Highlights Unicycive Therapeutics, Inc.

Equities

UNCY

US90466Y1038

Market Closed - Nasdaq Other stock markets 01:30:00 16/05/2024 am IST			5-day change	1st Jan Change
1.08 ^USD	-0.92%		-4.42%	+24.47%

13/05	Unicycive Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04/04	Piper Sandler Initiates Coverage on Unicycive Therapeutics With Overweight Rating, $9 Price Target	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Unicycive Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05	CI
Unicycive Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03	CI
Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate	08/03	CI
Unicycive Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	15/11	CI
Unicycive Therapeutics Reaches Alignment with the Fda on Path to File New Drug Application for Oxylanthanum Carbonate	23/23/23	CI
Unicycive Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	15/23/15	CI
Unicycive Therapeutics' Shares Drop After US FDA Requested Additional Information on Lanthanum Dioxycarbonate Program	30/23/30	MT
Unicycive Therapeutics, Inc. Provides Regulatory Update on Lanthanum Dioxycarbonate Program	30/23/30	CI
Unicycive Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	16/23/16	CI
UNICYCIVE THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	31/23/31	AQ
Unicycive Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	31/23/31	CI
Unicycive Therapeutics Enters Into License Accord With Lotus Pharmaceutical for Renazorb in South Korea	02/23/02	MT
Unicycive Therapeutics, Inc. Announces Exclusive License and Development Agreement with Lotus for Renazorb in the Republic of Korea	02/23/02	CI
Unicycive Therapeutics Says UK's MHRA Accepts to Start Phase 1 Trial of Drug Candidate to Treat Acute Kidney Injury	22/22/22	MT
Unicycive Therapeutics, Inc. Announces Medicines and Healthcare Products Regulatory Agency in the United Kingdom Complete Review of the Clinical Trial Application and Issue A Notice of Acceptance for UNI-494 First-In-Human Phase 1	22/22/22	CI
Unicycive Therapeutics, Inc. Reports Key Findings of Uni-494 Efficacy in Preclinical Animal Model of Geographic Atrophy	21/22/21	CI
UNICYCIVE THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)	14/22/14	AQ
Unicycive Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/22/14	CI
Unicycive Completes Enrollment of Pivotal Bioequivalence Study for Renazorb™ (Lanthanum Dioxycarbonate), an Investigational Treatment for Hyperphosphatemia in Chronic Kidney Disease Patients on Dialysis	10/22/10	CI
Unicycive Reports Key Findings of UNI-494 Efficacy in Preclinical Animal Model of Acute Kidney Injury	07/22/07	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Unicycive Therapeutics, Inc.

Equities

UNCY

US90466Y1038

Highlights

Filters